Eos Energy Enterprises Inc vs GE HealthCare Technologies Inc. Common Stock — how do they compare? Eos Energy Enterprises Inc trades at $1.91 (market cap $846.69M), while GE HealthCare Technologies Inc. Common Stock trades at $68.97 (market cap $31.07B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 36.7× Eos Energy Enterprises Inc's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals.
| EOSE | GEHC | |
|---|---|---|
Market Cap | $846.69M | $31.07B |
Volume | 19,531,326 | 3,443,020 |
Sector | Industrials | Health |
52-Week High | $19.19 | $88.16 |
52-Week Low | $1.95 | $59.48 |
Typical Hold Time | 17 Days | — |
Enterprise Value | $1.18B | $39.53B |
Dividend Yield | — | 0.23% |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $2.32, down 2.93% today, with bearish technical signals from moving averages despite oversold RSI readings. The company shows explosive revenue growth (from $114M in 2025 to $214M in 2026) but remains deeply unprofitable with negative gross margins and net losses. Recent catalysts include a $87M DOE loan advance and a Google partnership for a West Virginia energy project, driving positive media coverage.
The stock presents high-risk speculation with Wall Street analysts maintaining a cautious 'Hold' consensus (63.64%) despite a $7.10 price target implying 206% upside. Investment appeal hinges on EOSE scaling production and achieving profitability, but substantial execution risks and cash burn require careful monitoring. Current valuation at 4.46x sales appears stretched given persistent losses.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →